HALO News and Press, Halozyme Therapeutics Inc. From 02/16/24

2024-02-16 17:20:16 ET More on Halozyme Therapeutics Halozyme Therapeutics: A Reasonable Value In An Overvalued Market EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze Halozyme’s early 2023 results indicate a mixed performance Seeking Alp...

Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results PR Newswire SAN DIEGO , Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023...

2024-01-30 16:40:26 ET More on Johnson & Johnson Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy' Johnson & Johnson 2023 Q4 - Results -...

2024-01-30 12:05:00 ET Summary Bernzott Capital Advisors is an independent money manager for institutional and private clients. We are 100% owned by employees and an employee-related individual. Global financial markets rallied in 4Q, with small cap stocks leading the way. Des...

2024-01-30 07:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-29 17:25:44 ET More on Halozyme Therapeutics, Takeda Pharmaceutical, etc. Halozyme Therapeutics: A Reasonable Value In An Overvalued Market Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings...

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) PR Newswire SAN DIEGO , Jan. 29, 2024 /PRNewswire/ -- Halozyme Th...

2024-01-26 12:47:12 ET Summary Today, we take another look at Halozyme Therapeutics, Inc., which enhances drug delivery through its ENHANZE platform, earning royalties and milestone payouts from major drugmakers. Management has plans in place to more than double royalty revenues b...

2024-01-23 07:56:29 ET More on Genmab, J&J, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Genmab: 3 Trends To Track For A Strong 2024 And Beyo...

2024-01-19 09:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...